Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00837746

Enrollment

Registered

2009-02-05

Start date

2003-04-30

Completion date

2006-10-31

Last updated

2013-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and bone quality in postmenopausal women who had received long term therapy with risedronate.

Interventions

DRUGrisedronate

risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Completed month 36 of Study RVN-008993. * Underwent an iliac crest bone biopsy at month 36.

Exclusion criteria

* Was less than 60% compliant with regard to taking study drug from the start of the study drug to month 24 of study RVN-008993.

Design outcomes

Primary

Measure	Time frame
Differences in iliac crest bone histomorphometry and bone quality in patients receiving risedronate	5 years

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026